Journal of diabetes and its complications最新文献

{"title":"The prevalence of diabetic neuropathy in Greenland and its association with Inuit genetic ancestry - a cross-sectional study.","authors":"Marie Mathilde Bjerg Christensen, Christian Stevns Hansen, Jesper Fleischer, Ninna Senftleber, Frederik Filip Stæger, Torben Hansen, Daniel R Witte, Marit Eika Jørgensen","doi":"10.1016/j.jdiacomp.2025.109179","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2025.109179","url":null,"abstract":"<p><strong>Aims: </strong>Data on diabetic neuropathies in Greenland remains limited. The aim was to estimate the prevalence of diabetic peripheral neuropathy (DPN) and cardiovascular autonomic neuropathy (CAN) among Greenlanders with diabetes and prediabetes and investigate whether Inuit ancestry contributes to higher susceptibility.</p><p><strong>Methods: </strong>Individuals with diabetes and prediabetes from the Greenland Population Survey 2018 were examined for DPN (Vibration Perception Threshold (VPT) and light pressure) and CAN (Cardiovascular Reflex Tests and Heart Rate Variability). Inuit genetic admixture was included as a determinant in regression models adjusted for age, sex, genetics, diabetes status and residency.</p><p><strong>Results: </strong>Among 447 participants (1/3 diabetes, median age 61, 57 % female) DPN prevalence was 28 % in diabetes and 25 % in prediabetes. CAN prevalence was 24 % and 15 %, respectively. A 20-percentage point change in Inuit ancestry was associated with a 4 % higher VPT (coefficient: 1.04, 95 % CI: 1.003-1.08) and 51 % higher odds of CAN (OR: 1.51, 95 % CI: 1.09-2.08).</p><p><strong>Conclusions: </strong>DPN and CAN are common among Greenlanders with diabetes and prediabetes, highlighting the need for improved diagnostics and prevention. The association between Inuit genetic ancestry and neuropathy suggests a predisposition to neuropathy among Inuit, which may be explained by both genetic and lifestyle factors.</p>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"109179"},"PeriodicalIF":3.1,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A cross-sectional study.","authors":"Emir Muzurović, Goran Topić, Nevena Todorović, Manfredi Rizzo, Ksenija Zečević","doi":"10.1016/j.jdiacomp.2025.109147","DOIUrl":"10.1016/j.jdiacomp.2025.109147","url":null,"abstract":"<p><strong>Background: </strong>The severity of liver fibrosis serves as a crucial prognostic indicator, reflecting liver-related and cardiovascular-related outcomes, as well as mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Type 2 diabetes mellitus (T2DM) is a major risk factor for developing metabolic dysfunction-associated steatohepatitis (MASH), and in patients with both T2DM and MASH, identifying those with advanced fibrosis is critical.</p><p><strong>Methods: </strong>This cross-sectional study included 162 MASLD patients (47 with T2DM, 38 with prediabetes and 77 individuals without diabetes). The aim of this study was to determine the prevalence of advanced fibrosis in MASLD patients with and without DM and prediabetes, using a 2-step approach with fibrosis-4 index followed by liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE), and to evaluate the predictive cardiometabolic risk factors for the development of advanced fibrosis in these patients.</p><p><strong>Results: </strong>Among patients with prediabetes and T2DM, 12.9 % were identified with F3 stage fibrosis, 6.5 % had F4 stage, totaling 19.4 % with advanced fibrosis or cirrhosis, assessed by VCTE. In contrast, among individuals without diabetes, 1.78 % was found to have F3 stage fibrosis, while 7.14 % had F4. In patients with T2DM or prediabetes, body mass index (BMI) was a significant predictor of advanced fibrosis (p = 0.02), with each unit increase in BMI linked to a 1.3-fold higher risk of advanced fibrosis and cirrhosis, and higher high-density lipoprotein cholesterol (HDL-C) levels were associated with lower odds of having F3 or F4 stage fibrosis (p = 0.04). In MASLD patients without diabetes, triglycerides (TGs) showed a significant positive correlation with liver stiffness (p = 0.04), male sex was significantly associated with a higher susceptibility to increased liver stiffness (p = 0.04), and males had 0.91 times the odds of developing advanced fibrosis and cirrhosis (p = 0.02). No significant correlations were observed between liver stiffness and age, sex, aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose levels, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or TGs in patients with T2DM or prediabetes. In MASLD patients without diabetes, no significant correlations were found between liver stiffness and factors such as age, BMI, AST, ALT, TC, LDL-C, HDL-C, or glucose levels.</p><p><strong>Conclusion: </strong>In conclusion, the prevalence of advanced fibrosis or cirrhosis in patients with both, MASLD and T2DM, is very high. In MASLD patients with T2DM or prediabetes, higher BMI and lower levels of HDL-C are significant predictors of advanced fibrosis or cirrhosis.</p>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"109147"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can fibrate therapy redefine the management of diabetic retinopathy? A comprehensive systematic review and meta-analysis of efficacy and safety","authors":"Kai-Yang Chen ,&nbsp;Hoi-Chun Chan ,&nbsp;Chi-Ming Chan","doi":"10.1016/j.jdiacomp.2025.109178","DOIUrl":"10.1016/j.jdiacomp.2025.109178","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Diabetic retinopathy (DR) is a severe microvascular diabetes complication and a leading cause of preventable blindness. Fibrates, being lipid-lowering agents, have been found to have promise in modifying DR progression.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To determine fibrates' effectiveness and safety profile in reducing the incidence, progression, and severity of diabetic retinopathy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Randomized controlled trials and observational cohort studies that compared fibrate therapy with no fibrate therapy in patients with diabetes were eligible for this systematic review and meta-analysis. The outcomes of interest included the incidence of DR, long-term progression, progression to Proliferative Diabetic Retinopathy (PDR), and adverse effects. Risk of bias was assessed using the RoB 2 and ROBINS-I tools, and results were synthesized narratively due to heterogeneity in the study populations, follow-up durations, and diagnostic methods.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Only 17 articles were eligible for inclusion in this study. Fibrates significantly reduced the incidence of diabetic retinopathy (OR 0.72 (95 % CI: 0.66–0.77), &lt;em&gt;p&lt;/em&gt; &lt; 0.001; I&lt;sup&gt;2&lt;/sup&gt; = 26.53 %) and slowed long-term progression (OR 0.67 (95 % CI: 0.57–0.79), p &lt; 0.001).; I&lt;sup&gt;2&lt;/sup&gt; = 26.39 %) compared to placebo. Combining fibrates with statin reduces DR progression by 17 % compared to fibrate alone HR 0.84 (95 % CI: 0.80–0.89), &lt;em&gt;p&lt;/em&gt; &lt; 0.001; I&lt;sup&gt;2&lt;/sup&gt; = 31.7 %. While progression to proliferative diabetic retinopathy showed a favorable trend (RR 0.71 (95 % CI: 0.15–3.32), &lt;em&gt;p&lt;/em&gt; = 0.67, the result was not statistically significant. Analysis of adverse events, including all-cause mortality (OR 0.86 (95 % CI: 0.62–1.19), &lt;em&gt;p&lt;/em&gt; = 0.36; I&lt;sup&gt;2&lt;/sup&gt; = 0 %), revealed no significant safety benefits in comparison between fibrates and placebo.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Fibrates significantly reduce both the incidence and long-term progression of diabetic retinopathy. Safety analyses revealed no significant difference between placebo and fibrates in reducing serious adverse events or all-cause mortality.&lt;/div&gt;&lt;div&gt;&lt;strong&gt;What is known about this research topic?&lt;/strong&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Diabetic retinopathy (DR) is a leading cause of preventable blindness, with limited systemic therapies beyond glycemic and blood pressure control.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Fibrates, primarily lipid-lowering agents, have shown potential benefits for microvascular complications, including DR, in trials like FIELD and ACCORD Eye.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;What this study adds and its future implications&lt;/strong&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;This meta-analysis confirms fibrates significantly reduce the incidence and long-term progression of DR, with fenofibrate showing the greatest benefit.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Alt","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109178"},"PeriodicalIF":3.1,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroinflammation and osteomyelitis in adults with Type 2 diabetes mellitus and peripheral neuropathy without and with foot lesions. What comes first?","authors":"Maria Sambataro, Luisa Sambado, Mayra Colardo, Anna Furlan, Piero Maria Stefani, Elisabetta Durante, Antonio Antico, Stefania Conte, Silvia Della Bella, Laura Nollino, Zavan Barbara, Nicola Menegotto, Elisa Vian, Marco Segatto, Matteo Fassan","doi":"10.1016/j.jdiacomp.2025.109176","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2025.109176","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aims: &lt;/strong&gt;Diabetic foot is the leading cause of both major and minor non-traumatic amputations yet a truly understanding of the phenomenon is still lacking. The updated definition for diabetes-related foot disease from the International Working Group on the Diabetic Foot (IWGDF 2023 update) is \"disease of the foot of a person with current or previously diagnosed diabetes mellitus that includes one or more of the following: peripheral neuropathy, peripheral artery disease, infection, ulcer(s), neuro-osteoarthropathy, gangrene, or amputation\", but what comes first? Our hypothesis is that distal sensory and autonomic neuropathy activate neuroischemic signaling and dysregulation of bone cell apoptosis portending to infections.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We studied 374 adults with Type 2 diabetes mellitus (T2DM) and diabetic neuropathy (DN) divided into the following subgroups: 106 partecipants without foot lesions (DNp); 119 nonmacrovascular partecipants with ulcers/lesions/osteomyelitis (DNpU); 149 revascularized partecipants with ulcers/lesions/osteomyelitis (DNpUV) and a group of 53 healthy adults as healthy control (NC). During routine foot care visits participants underwent neuro electrophysiology tests and vascular assessment. Biopsy specimens from exposed bone (grade III University of Texas wound classification, TUC) were cultured according to microbiological standards and histological analysis was performed. Pro/anti-inflammatory cytokines and blood cells subsets (lymphocytes subpopulations, classical, non-classical and SLAN&lt;sup&gt;+&lt;/sup&gt; monocytes, classical DCs, innate lymphoid cells) were analyzed. Nerve Growth Factor (NGF) species, fractalkine/CX3CL1 migration marker, autophagy markers (Ulk1, Beclin1, LC3, and p62), pro/anti-apoptotic proteins (Bax, Bcl2, cleaved Caspase-3), signal transduction of proteins involved in inflammation and cell survival (p65-NF-kB, Akt and ERK1/2) were measured.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Sural nerve (sS) conduction velocity (CV) and sensory Action Potential (sAP) thresholds defined DN. II and III TUC associates with progressive worsening of neuronal function while vibration perception threshold (VPT) and systolic/diastolic orthostatic hypotension inversely correlated with TcPO&lt;sub&gt;2&lt;/sub&gt; and critical ischemia. In III TUC versus I TUC diabetic foot ulcer (DFU) and DNp samples the amount of circulating mature NGF (mNGF) was significantly reduced (p &lt; 0.01) while immature NGF (proNGF) was significantly increased (p &lt; 0.05). In all groups we found higher number of SLAN+ monocytes co-expressing CX3CR1 directly correlating with proNGF levels, worse autonomic and sensory testing and inversely correlating with mNGF levels, sensory nerves CV and AP, innate lymphoid cells and subsets of lymphocytes. Surprisingly, we found 59 bone's biopsies with an altered histological pattern but negative microbiological cultures. In all biopsied patients CX3CR1-SLAN+ cells were significantly elevated (p &lt; 0.0","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"109176"},"PeriodicalIF":3.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The cardiovascular–kidney–metabolic staging in type 2 diabetes: the clock starts ticking early","authors":"Karolina Hoffmann ,&nbsp;Anna Paczkowska ,&nbsp;Viviana Maggio ,&nbsp;Manfredi Rizzo","doi":"10.1016/j.jdiacomp.2025.109177","DOIUrl":"10.1016/j.jdiacomp.2025.109177","url":null,"abstract":"<div><div>Nishizawa et al. demonstrate that cardiovascular–kidney–metabolic (CKM) staging is a strong predictor of all-cause mortality in type 2 diabetes, even before contemporary ardiorenal therapies were widely available. In their cohort, mortality rose sharply from stage 3 onward, underscoring that pathological risk begins well before overt cardiorenal failure. Because CKM staging relies on routine clinical data, it offers a pragmatic framework for early risk stratification, yet it is often applied too late. Integrating CKM assessment into electronic health systems and initiating cardiorenalprotective interventions in stages 1–2 could substantially improve outcomes. Future studies should validate CKM staging in modern therapy settings and evaluate stageguided interventions.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109177"},"PeriodicalIF":3.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in China","authors":"Zeyu Xie ,&nbsp;Zhuoru Liang ,&nbsp;Guimei Zheng ,&nbsp;Weiling Cao","doi":"10.1016/j.jdiacomp.2025.109174","DOIUrl":"10.1016/j.jdiacomp.2025.109174","url":null,"abstract":"<div><h3>Background</h3><div>As a structurally unique peroxisome proliferator-activated receptor pan-agonist, chiglitazar has showed dual therapeutic benefits for glycemic control and lipid management in type 2 diabetes mellitus (T2DM). Despite these clinical advantages, comprehensive pharmacoeconomic evaluations comparing chiglitazar with conventional therapies like sitagliptin remain unavailable for China's healthcare system.</div></div><div><h3>Objective</h3><div>This study aimed to conduct a comparative cost-utility analysis of chiglitazar versus sitagliptin for T2DM treatment in China, evaluating long-term clinical and economic outcomes from a healthcare system perspective.</div></div><div><h3>Methods</h3><div>Data on patient demographics and post-treatment effects were collected from a double-blind, phase 3, randomized controlled trial conducted in China. The United Kingdom Prospective Diabetes Study Outcomes Model 2.1 was employed to evaluate the long-term effectiveness and associated costs. Uncertainties were addressed using one-way and probabilistic sensitivity analyses. Additionally, the binary search method was utilized to estimate an optimal annual cost for sitagliptin in scenario analyses.</div></div><div><h3>Results</h3><div>After a 40-year simulation, the life expectancy results were comparable among treatments: 14.93 years for chiglitazar 32 mg, 14.94 years for chiglitazar 48 mg, and 14.93 years for sitagliptin 100 mg. The corresponding quality-adjusted life years (QALYs) reached 12.82, 12.83, and 12.81, respectively. Total accumulated costs over the simulation period were $44,241.09 (chiglitazar 32 mg), $45,044.25 (chiglitazar 48 mg), and $44,821.45 (sitagliptin 100 mg). Long-term economic evaluation revealed that chiglitazar 32 mg provided the optimal cost-effectiveness, whereas sitagliptin 100 mg was the least economically advantageous option. Both one-way and probabilistic sensitivity analyses confirmed the robustness of these findings. Scenario analysis showed that sitagliptin 100 mg only becomes cost-effective when its annual cost is reduced by at least 42.33 % compared to chiglitazar 32 mg.</div></div><div><h3>Conclusion</h3><div>Based on cost-utility analysis within the Chinese healthcare context, chiglitazar demonstrates significantly better long-term health outcomes and cost-effectiveness relative to sitagliptin for T2DM management.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109174"},"PeriodicalIF":3.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial","authors":"Maryam A. Rizk ,&nbsp;Sahar M. El-Haggar ,&nbsp;Osama M. Ibrahim ,&nbsp;Hossam Arafa Ghazi","doi":"10.1016/j.jdiacomp.2025.109175","DOIUrl":"10.1016/j.jdiacomp.2025.109175","url":null,"abstract":"<div><div>Globally, the prevalence of diabetes mellitus is rising. One of the main causes of end-stage renal disease (ESRD) and a risk factor for higher morbidity and death in diabetic patients is diabetic nephropathy (DN), sometimes referred to as diabetic kidney disease (DKD). DN, a microvascular consequence of diabetes, affects 20–40 % of diabetics globally. The study's objective was to assess if levocetirizine may have albuminuria lowering effect and anti-inflammatory effect in patients treated with angiotensin receptor blockers (ARBs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors therapy by reducing albuminuria and improving DKD indicators.</div></div><div><h3>Patients and methods</h3><div>A controlled, parallel, trial was carried out on sixty DKD patients. Sixty patients were divided into two groups at random. Group 1 (control group) received an empagliflozin 10 mg once day in addition to 80 mg valsartan. Group 2 (levocetirizine group) received the same medications as the control group plus a 5 mg of levocetirizine once daily in the evening, titrated dose based on each patient's creatinine clearance (CrCl) for three months. Serum creatinine, serum urea, serum cystatin-C, HbA₁c, tumor necrosis factor alpha (TNF-α), estimated glomerular filtration rate (eGFR), and urinary albumin to creatinine ratio (UACR) were measured at baseline and compared to these data three months after drug administration.</div></div><div><h3>Results</h3><div>Levocetirizine decreased significantly UACR at the end of the three-months (<em>p</em> = 0.037) compared to the control group. There was no variation in eGFR between the two groups, eGFR was significantly lower than baseline (<em>p</em> &lt; 0.001) in both groups. Comparing the levocetirizine group to the control group, there is a substantial drop in TNF-α (<em>p</em> = 0.004), cystatin-C (<em>p</em> = 0.034), and HbA₁c (<em>p</em> = 0.007).</div></div><div><h3>Conclusion</h3><div>Levocetirizine reduces albuminuria, inflammatory, and renal indicators, which makes it a potentially has albuminuria lowering effect and anti-inflammatory drug which decreases disease progression.</div></div><div><h3>Trial registration identifier</h3><div><span><span>NCT05638880</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109175"},"PeriodicalIF":3.1,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00220-X","DOIUrl":"10.1016/S1056-8727(25)00220-X","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109167"},"PeriodicalIF":3.1,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between flow-mediated dilation and urinary albumin-creatinine ratio in patients with type 2 diabetes mellitus","authors":"YuDie Fang ,&nbsp;Lijuan Jing ,&nbsp;YunXia Zhu ,&nbsp;Hongping Wang ,&nbsp;Juan Xia ,&nbsp;Tao Lei ,&nbsp;Jun Lu ,&nbsp;Jie Gao","doi":"10.1016/j.jdiacomp.2025.109162","DOIUrl":"10.1016/j.jdiacomp.2025.109162","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the association between Flow-Mediated Dilation (FMD) and the urinary albumin-to-creatinine ratio (UACR) in individuals with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>This cross-sectional study involved 194 individuals diagnosed with T2DM. Participants were categorized into two groups based on their UACR levels: the diabetic kidney disease group (DKD) (UACR≥30 mg/g) and the non-diabetic kidney disease group (non-DKD) (UACR &lt;30 mg/g). The relationship between FMD and UACR was evaluated through Spearman correlation analysis and multivariable logistic regression analysis. Additionally, the predictive capacity of FMD for DKD was determined using receiver operating characteristic curve analysis.</div></div><div><h3>Results</h3><div>Median FMD was lower in DKD group than in non-DKD group (3.9 vs 4.9, <em>p</em> = 0.011). Furthermore, a notable negative correlation was observed between FMD and UACR (<em>r</em> = −0.253, <em>p</em> &lt; 0.05). Through logistic regression analysis, an increase in FMD by one standard deviation (SD) corresponded to a 35.6 % decrease in the likelihood of elevated UACR (OR: 0.644 [0.459–0.904]) (Model 1). Consistent findings were noted even after accounting for variables such as sex, age, BMI, hypertension, smoking habits, and alcohol intake (Model 2), as well as HbA1c levels, disease duration, and triglycerides (Model 3). The area under the ROC curve (AUC) for FMD was 0.686 (95 % CI 0.596–0.777).</div></div><div><h3>Conclusions</h3><div>FMD is independently correlated with UACR, which provides a clinical basis for the prevention and control of vascular complications in early DKD.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109162"},"PeriodicalIF":3.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in mean serum insulin and hyperinsulinemia among US adults without diabetes 1999–2018","authors":"Tammie M. Johnson ,&nbsp;James R. Churilla","doi":"10.1016/j.jdiacomp.2025.109159","DOIUrl":"10.1016/j.jdiacomp.2025.109159","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study is to examine trends for mean serum insulin concentration (pmol/L) and prevalence of hyperinsulinemia (≥4.358 pmol/L fasting insulin) in US adults without diabetes.</div></div><div><h3>Methods</h3><div>We used data from the 1999–2018 National Health and Nutrition Examination Survey (NHANES). Participants (<em>n</em> = 14,150) were ≥20 years of age, not pregnant, had no history of diabetes, had a fasting blood glucose measure of less than 126 mg/dL, and had valid responses to all study variables. Consecutive cycles of NHANES data from 1999 to 2018 (20 years) were aggregated into five four-year intervals.</div></div><div><h3>Results</h3><div>The Annual Percent Change (APC) for mean fasting insulin ranged from 5.64 (adjusted for body mass index) to 7.65 % when unadjusted (all <em>p</em>-values for trend &lt;0.0001). The APC for hyperinsulinemia prevalence ranged from 19.4 % (adjusted for waist circumference) to 22.3 % when unadjusted (all <em>p</em>-values for trend &lt;0.0001). The subanalyses by gender consistently revealed significant positive trends for both outcomes.</div></div><div><h3>Conclusions</h3><div>This study illustrates a significant positive trend for mean fasting insulin concentrations and hyperinsulinemia among US adults over 20 years. Monitoring serum insulin and hyperinsulinemia trends provides insights into the continuing rise in type 2 diabetes (T2D) and opportunities for T2D prevention.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109159"},"PeriodicalIF":3.1,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}